Di Cesare, A. et al. 2025. Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study. Dermatology Practical & Conceptual. 15, 4 (Oct. 2025), 5733. DOI:https://doi.org/10.5826/dpc.1504a5733.